CD8A and relapsing-remitting multiple sclerosis: Resembling the strategy for CD8+ T lymphocytes, we performed UMAP analyses in CD3-CD19+ B cells from untreated RRMS patients and treated RRMS patients during FTY or NTZ therapies.